Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

N Engl J Med. 2017 Nov 23;377(21):2098. doi: 10.1056/NEJMc1712572.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Canagliflozin*
  • Cardiovascular System
  • Diabetes Mellitus, Type 2*
  • Humans
  • Hypoglycemic Agents
  • Kidney

Substances

  • Hypoglycemic Agents
  • Canagliflozin